Prognostic impact of CEBPA bZIP domain mutation in acute myeloid leukemia

Wakita, Satoshi; Sakaguchi, Masahiro; Oh, Iekuni; Kako, Shinichi; Toya, Takashi; Najima, Yuho; Doki, Noriko; Kanda, Junya; Kuroda, Junya; Mori, Shinichiro; Satake, Atsushi�; Usuki, Kensuke; Ueki, Toshimitsu; Uoshima, Nobuhiko; Kobayashi, Yutaka; Kawata, Eri; Tajika, Kenji; Nagao, Yuhei; Shono, Katsuhiro; Shibusawa, Motoharu; Tadokoro, Jiro; Kayamori, Kensuke; Hagihara, Masao; Uchiyama, Hitoji; Uchida, Naoyuki; Kubota, Yasushi; Kimura, Shinya; Nagoshi, Hisao; Ichinohe, Tatsuo; Kurosawa, Saiko; Motomura, Sayuri; Hashimoto, Akiko; Muto, Hideharu; Sato, Eriko; Ogata, Masao; Mitsuhashi, Kenjiro; Ando, Jun; Marumo, Atsushi; Omori, Ikuko; Fujiwara, Yusuke; Terada, Kazuki; Yui, Shunsuke; Arai, Kunihito; Kitano, Tomoaki; Miyata, Miho; Kurosawa, Akiyo; Mizoguchi, Ayumi; Komatsu, Norio; Fukuda, Takahiro; Ohashi, Kazuteru; Kanda, Yoshinobu; Inokuchi, Koiti; Yamaguchi, Hiroki

doi:10.1182/bloodadvances.2021004292

Public

Prognostic impact of CEBPA bZIP domain mutation in acute myeloid leukemia

Published in Blood Advances • Aug 27, 2021

Authors:

Satoshi Wakita

Masahiro Sakaguchi

Iekuni Oh

Abstract

Mutations of CCAAT/enhancer-binding protein alpha (CEBPAmu) are found in 10% to 15% of de novo acute myeloid leukemia (AML) cases. Double-mutated CEBPA (CEBPAdm) is associated with a favorable prognosis; however, single-mutated CEBPA (CEBPAsm) does not seem to improve prognosis. We investigated CEBP...

Subject

CEBPA

bZIP domain

NPM1

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!